NorthRock Partners LLC Boosts Stake in Thermo Fisher Scientific Inc. (NYSE:TMO)

NorthRock Partners LLC grew its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 32.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 4,458 shares of the medical research company’s stock after acquiring an additional 1,093 shares during the quarter. NorthRock Partners LLC’s holdings in Thermo Fisher Scientific were worth $2,319,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Aprio Wealth Management LLC lifted its stake in Thermo Fisher Scientific by 17.9% during the fourth quarter. Aprio Wealth Management LLC now owns 1,022 shares of the medical research company’s stock worth $532,000 after purchasing an additional 155 shares during the last quarter. Fiduciary Alliance LLC bought a new stake in Thermo Fisher Scientific in the 4th quarter worth approximately $811,000. Capital Investment Advisors LLC boosted its stake in Thermo Fisher Scientific by 15.4% in the fourth quarter. Capital Investment Advisors LLC now owns 1,335 shares of the medical research company’s stock worth $695,000 after buying an additional 178 shares in the last quarter. Signet Financial Management LLC purchased a new position in shares of Thermo Fisher Scientific during the fourth quarter worth approximately $218,000. Finally, Benson Investment Management Company Inc. boosted its stake in shares of Thermo Fisher Scientific by 0.7% in the 4th quarter. Benson Investment Management Company Inc. now owns 8,149 shares of the medical research company’s stock valued at $4,239,000 after purchasing an additional 53 shares in the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the business’s stock in a transaction dated Monday, April 28th. The stock was sold at an average price of $429.93, for a total transaction of $128,979.00. Following the completion of the sale, the executive vice president now directly owns 23,167 shares in the company, valued at $9,960,188.31. The trade was a 1.28% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Michael A. Boxer sold 3,775 shares of the stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $532.52, for a total transaction of $2,010,263.00. Following the completion of the transaction, the senior vice president now owns 10,816 shares in the company, valued at $5,759,736.32. This trade represents a 25.87% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 14,075 shares of company stock worth $7,305,942 in the last ninety days. Insiders own 0.33% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently commented on TMO. UBS Group decreased their price objective on Thermo Fisher Scientific from $715.00 to $500.00 and set a “buy” rating on the stock in a report on Thursday, April 24th. Citigroup decreased their target price on shares of Thermo Fisher Scientific from $650.00 to $570.00 and set a “neutral” rating on the stock in a research note on Tuesday, March 4th. Robert W. Baird dropped their price target on shares of Thermo Fisher Scientific from $603.00 to $573.00 and set an “outperform” rating for the company in a research report on Thursday, April 24th. Raymond James reaffirmed an “outperform” rating and set a $667.00 price objective (up from $650.00) on shares of Thermo Fisher Scientific in a research note on Monday, February 3rd. Finally, Barclays cut their target price on Thermo Fisher Scientific from $620.00 to $475.00 and set an “equal weight” rating on the stock in a research note on Thursday, April 10th. Five analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $607.43.

Thermo Fisher Scientific Stock Down 0.9%

Thermo Fisher Scientific stock opened at $428.88 on Wednesday. The firm has a market cap of $161.90 billion, a price-to-earnings ratio of 25.95, a PEG ratio of 2.99 and a beta of 0.82. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59. Thermo Fisher Scientific Inc. has a 12 month low of $401.75 and a 12 month high of $627.88. The stock has a fifty day simple moving average of $460.85 and a two-hundred day simple moving average of $513.11.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, topping analysts’ consensus estimates of $5.10 by $0.05. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. The business had revenue of $10.36 billion during the quarter, compared to analyst estimates of $10.23 billion. During the same quarter in the previous year, the firm earned $5.11 EPS. Thermo Fisher Scientific’s revenue was up .2% on a year-over-year basis. Equities analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, April 15th. Shareholders of record on Friday, March 14th were paid a dividend of $0.43 per share. The ex-dividend date of this dividend was Friday, March 14th. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. This represents a $1.72 dividend on an annualized basis and a yield of 0.40%. Thermo Fisher Scientific’s payout ratio is currently 10.09%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.